Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate

Chin Med J (Engl). 2012 Jul;125(14):2636-7.


Imatinib mesylate is a molecular targeted agent for treating chronic myeloid leukemia (CML) and gastrointestinal stromal tumor. Although imatinib mesylate is not regarded as an immunosuppressive agent, few studies have also shown that it may impair immune response. In this report, we present a case of transient hepatitis B virus (HBV) reactivation during imatinib mesylate treatment for CML.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Benzamides
  • Hepatitis B virus / pathogenicity*
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / virology*
  • Male
  • Piperazines / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Virus Replication / drug effects


  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate